# Screening for Systemic Light-Chain Amyloidosis in Patients Over 60 with λ Monoclonal Gammopathies

**Authors:** Ping Zhou, Mahesh M. Mansukhani, Raymond Yeh, Jiesheng Lu, Hongai Xia, Lahari Koganti, Jiuhong Pang, Denis Toskic, Stephanie Scalia, Xun Ma, Lisa X. Lee, Sandy W. Wong, Alfred Chung, Sascha A. Tuchman, Terry Fogaren, Nancy Coady Lyons, Cindy Varga, Suzanne Lentzsch, Raymond L. Comenzo

PMC · DOI: 10.3390/jcm14124146 · Journal of Clinical Medicine · 2025-06-11

## TL;DR

This study screens older patients with λ monoclonal gammopathies for early signs of a serious condition called light-chain amyloidosis to improve early diagnosis and reduce mortality.

## Contribution

The study identifies specific genetic markers and clinical features that can help screen for light-chain amyloidosis in high-risk patients.

## Key findings

- AL was confirmed in 3 out of 17 SMM patients through tissue biopsy.
- AL-related IGVL genes and t(11;14) or gain 1q were more common in SMM patients with AL.
- The study suggests a larger screening effort to develop a diagnostic algorithm for AL.

## Abstract

Background/Objectives: To reduce the early mortality of light-chain amyloidosis (AL), earlier diagnosis is needed. To pursue this goal, we conducted a multicenter study screening for AL λ-type (NCT04615572) in subjects > 60 years of age with λ smoldering myeloma (SMM) or monoclonal gammopathy of undetermined significance (MGUS), a light-chain differential (dFLC, λ minus κ) > 23 mg/L, and no prior amyloid diagnosis. Methods: Variables included AL-related IGVL gene usage and clonal plasma cell cytogenetic abnormalities, such as t(11;14) or gain 1q, which are present in 75% of AL cases. Here, 9 out of 33 λ IGVL genes, accounting for 90% of AL λ cases, were considered to be AL-related. Bone marrow was obtained, plasma cell cytogenetics and next generation sequencing for IGVL genes were performed, and subjects with AL-related IGVL genes were screened for AL using tissue studies. Results: From 2021 to 2023, we enrolled 30 subjects (19 M/11 F) with a median age of 68.5 years old (IQR 64.3–73), 17 SMM and 13 MGUS, with a median of 6% marrow plasma cells (range, 3.5–40). Here, 11 SMM and 4 MGUS cases had t(11;14) or gain 1q; 10/17 SMM and 12/13 MGUS had AL-related genes, and AL was ultimately confirmed by tissue biopsy in 3 with SMM. SMM, AL-related IGVL genes, and t(11;14) or gain 1q were found in 6 SMM subjects, including the 3 with AL (3/6 vs. 0/16; p < 0.05, Fisher’s exact, two-tailed). Conclusions: These results justify a larger study screening for AL in SMM to develop a likelihood algorithm for AL using dFLC, IGVL gene usage, and the presence of t(11;14) or gain 1q.

## Linked entities

- **Genes:** LOC100713050 (immunoglobulin lambda-1 light chain-like) [NCBI Gene 100713050]
- **Diseases:** light-chain amyloidosis (MONDO:0019438), smoldering myeloma (MONDO:0005235), monoclonal gammopathy of undetermined significance (MONDO:0004225)

## Full-text entities

- **Diseases:** lambda Monoclonal Gammopathies (MESH:D010265), MGUS (MESH:D008998), amyloid (MESH:C000718787), Light-Chain Amyloidosis (MESH:D000075363), AL (MESH:D000686)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12193820/full.md

## Figures

1 figure with captions in the complete paper: https://tomesphere.com/paper/PMC12193820/full.md

## References

37 references — full list in the complete paper: https://tomesphere.com/paper/PMC12193820/full.md

---
Source: https://tomesphere.com/paper/PMC12193820